Approval · Notice of Compliance 10439 · 2009
PLAVIX: Notice of Compliance 10439
Issued July 22, 2009
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 10439
- Date
- July 22, 2009
- Company
- Sanofi-Aventis Canada Inc.Toronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New strength: 300 mg
- Therapeutic class
- Platelet aggregation inhibitor
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| PLAVIX | 02330555 | Cancelled Post Market |
Medicinal ingredients
- CLOPIDOGREL BISULFATE 300 MG per TAB